MYF-01-37

Cas No.:	2416417-65-5
Chemical Name:	Schembl21958179
Synonyms:	s8950;1-(3-Methyl-3-((3-(trifluoromethyl)phenyl)amino)pyrrolidin-1-yl)prop-2-en-1-one;Schembl21958179
SMILES:	FC(C1C([H])=C([H])C([H])=C(C=1[H])N([H])C1(C([H])([H])[H])C([H])([H])N(C(C([H])=C([H])[H])=O)C([H])([H])C1([H])[H])(F)F
Formula:	C15H17F3N2O
M.Wt:	298.3035
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

MYF-01-37 is a covalent TEAD inhibitor targeting Cys380. MYF-01-37 has a reversible inhibition on YAP/TEAD interaction[1].

In Vitro:

MYF-01-37 (10 μM; 24h) results in inhibition of direct YAP/TEAD interaction in HEK 293T cells, and in the reduction in canonical YAP target gene CTGF expression in PC-9 cells[1]. MYF-01-37 (0.1, 1, 10, 100 μM) has minimal impact on cell viability of several EGFR-mutant NCSLC cell lines[1]. MYF-01-37 (10 μM; 10 days) combinated with OT (combination of osimertinib and trametinib) leads to a dramatic decrease in dormant cells compared to OT alone[1].